Male sexual disorders

Authors

  • Asher Ahmed Mashhood
  • Shahzad Rauf
  • Shaukat Mehmood Qureishi

Keywords:

Sexual dysfunctions, impotence, orgasmic disorders, premature ejaculation, masturbation, dhat syndrome, phosphodiesterase type-5 inhibitors, selective serotonin reuptake inhibitors

Abstract

In men sexual dysfunction refers to repeated impairment of normal sexual interest and/ or performance. What is regarded as normal sexual intercourse and what is thought to be impaired or unsatisfactory, depends in part on the expectations of the two individuals concerned. For example one couple may regard it as normal that the woman is regularly unable to achieve orgasm, whilst another may seek treatment. The problems of sexual dysfunction include those affecting sexual desire and sexual enjoyment, erectile impotence and premature ejaculation.

References

Diagnostic and Statistical Manual of Mental Disorder, 4th edition. Washington DC: American Psychiatric Association; 2000.

Laumann EO, Gagnon JH, Michaels RT, Michaels S. The social organization of sexuality. Chicago: University of Chicago Press; 1994.

Dunn KM, Croft PR, Hackett TI. Sexual problems: a study of the prevalence and need for health care in the general population. Good Family Practice 1998; 15: 519-24.

Oksuz E, Malhan S. The prevalence of male sexual dysfunction and potential risk factors in Turkish men: a Web-based survey. Int J Impot Res 2005; 17: 539-45.

Taylor HA Jr. Sexual activity and cardiovascular patients: guidelines. Am J Cardio 1999; 84: 6N-10N.

Hawton KE, Oppenheimer C. Women’s sexual problems. In: Anderson A, McPherson A, eds. Women’s Problem in General Practice. Oxford: Oxford University Press; 1983.

Rosen RC, Leiblum SR. Current approaches to the evaluation of sexual desire disorders. J Sex Res 1987; 23: 141-62.

Kinsey AC, Pomeroy WB, Martin CE. Sexual Behavior in Human Males. Philadelphia: WB Saunders, 1948.

Kirby RS, Carson C, Webster GD. Impotence: diagnosis and management. Oxford: Butterworth Heinemann; 1991.

Zippe C, Nandipati K, Agarwal A, Raina R. Sexual dysfunctions after pelvic surgery. Int J Impot Res 2005;18: 1-18.

Burnett AL. Erectile dysfunction following radical prostatectomy. JAMA 2005; 293: 2648-53.

Leungwattanakij S, Roongreungslip U, Lertsithichai P. The association between erectile function and severity of lower urinary tract symptoms. J Med Assoc Thai 2005; 88: 91-5.

Koseoglu N, Koseoglu H, Ceylan E, Cimrin HA, Ozalevi S. Erectile dysfunction prevalence and sexual function status in patients with chronic obstructive pulmonary disease. J Urol 2005; 174: 249-52.

Vela NR, Garcia CJV, Cabrera PJ, Gonzalez EC. Impotence and cardiovascular disease: a new prospective in health-care compromise of the urologist. Arch Esp Urol 2005; 58: 43-53.

Corona G, Mannucci E, Petrone L, Ricca V. Psychobiological correlates of smoking in patients with erectile dysfunctions. Int J Impot Res 2005 Jun 2; [Epud ahead of print].

Esposito K, Giugliano D. Obesity, the metabolic syndrome and sexual dysfunction. In J Impot Res 2005; **May 19; [Epud ahead of print].

Althof SE, Seftel AD. The evaluation and management of erectile dysfunctions. Psych Clin N Am 1995; 1: 171-92.

Master WH, Johnson VE. Human Sexual Inadequacy. London: Churchill Livingstone; 1970.

Wang W, Kumar P, Minhas S, Ralph D. Proposal of findings for a new approach about how to define and diagnose premature ejaculation. Eur Urol 2005; 48; 418-23.

Yuan YM, Xin ZC, Jiang H, Guo YJ. Sexual function of premature ejaculation patients assayed with Chinese Index of Premature Ejaculation. Asian J Androl 2004; 6: 121-6.

Perme B, Ranjith G, Mohan R, Chanderasekaran R. Dhat (semen loss) syndrome: a functional somatic syndrome of the Indian subcontinent? Gen Hosp Psychiatry 2005; 27: 215-7.

Mumford DB. The ‘Dhat syndrome’: a culturally determined symptom of depression? Acta Psychiatr Scand 1996; 94: 163-7.

Bhatia MS, Bohra N, Malik SC. ‘Dhat’ syndrome- a useful clinical entity. Indian J Dermatol 1989; 34: 32-41.

Hawton KE. Sex Therapy: A Practical Guide. Oxford: Oxford University Press; 1985.

Heinman JR, LoPiccolo J. Clinical outcome of sex therapy. Arch Gen Psychiatry 1983; 40: 443-9.

Jiann BP, Yu CC, Su CC, Tsai JY. Compliance of sildenafil treatment for erectile dysfunction and factors affecting it. Int J Impot 2005;** Aug 11; [Epud ahead of print].

Nehra A, Grantmyre J, Nadel A, Thibonnier M, Brock G. Verdenafil improves patient satisfaction with erectile hardness, orgasmic function and sexual experience in men with erectile dysfunction following nerve sparing radical prostatectomy. J Urol 2005; 173: 2067-71.

McMahon CG, Stuckey BG, Lording DW, Witteret GA et al. A 6-month study of the efficacy and safety of taldalafil in the treatment of erectile dysfunction: a randomized, double-blind, parallel-group, placebo-controlled study in Australian men. Int J Clin Pract 2005; 59: 143-9.

Kamatenesi-Mugisha M, Oryem-Origa H. Traditional herbal remedies used in the management of sexual impotence and erectile dysfunction in Western Uganda. Afr Health Sci 2005; 5: 40-9.

Virag R. Intracavernosus injection of papaverine for erectile failure. Lancet 1982; 2. 938.

Padam-Nathan H, Goildstein I, Payton T, Krane RJ. Intracavernosal pharmacotherapy: the pharmacological erection program. World J Uro 1987; 5: 160-5.

Lee LM, Stevenson RW, Szasz G. Prostaglandin E1 versus phentolamine/papaverine for the treatment of erectile impotence: a double-blind comparison. J Urol 1988; 141: 54-7.

Linert OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. N Eng J Med 1996; 334: 873-7.

Padam-Nathan H, Hellstrom WG, Kaiser FE et al. Treatment of men with erectile dysfunctions with transurethral alprostadil. N Eng J Med 1997; 336: 1-7.

Witherington R. Vacuum constriction device for the management of erectile impotence. J Urol 1989; 141: 320-2.

Goldstein I. Arterial revascularization procedures. Sem Urol 1986; 4: 252-8.

Wylie K. Physical treatments for sexual dysfunctions. In: Freeman H, Pullen G, Stein G, Wilkinson G, eds. Psychosexual Disorders. London: Gaskell: 1998. p. 59-83.

Ralph D, McNicolas T. Management guidelines for erectile dysfunction. BMJ 2000; 321: 499-503.

Moreland AJ, Makela EH. Selective serotonin-reuptake inhibitors in the treatment of premature ejaculation. Ann Pharmacother 2005; 39: 1296-301.

Piediferro G, Colpi EM, Castiglioni F. Premature ejaculation.3. Therapy. Arch Ital Urol Androl 2004; 76: 192-8.

Waldinger MD, Olivier B. Utility of selective serotonin reuptake inhibitors in premature ejaculation. Curr Opin Investig Drugs 2004; 5: 743-7.

Rivera P, Gonzalez R. Gonzalez F, Storme O. Use of paroxetine on-demand in premature ejaculation. Actas Urol Esp 2005; 29: 387-91.

Waldinger MD. Lifelong premature ejaculation: definition, serotonergic neurotransmission and drug treatment. World J Urol 2005; 23: 102-8.

Abdel-Hamid IA. Phoshodiesterase 5 inhibitors in rapid ejaculation: potential use and possible mechanisms of actions. Drugs 2004; 64: 13-26.

Zhang XS, Wang YX, Huang XY et al. Comparison between sildenafil plus sertraline and sertraline alone in the treatment of premature ejaculation. Zhonghua Nan KeXue 2005; 11: 520-2 Chinese.

Assalian P. Guidelines for pharmacotherapy of premature ejaculation. World J Urol 2005; 23: 127-9.

Busato W, Galindo CC. Topical anaesthetic use for treating premature ejaculation: a double-blind, randomized, placebo-controlled study. BJU Int 2004; 93: 1018-21.

Downloads

Published

2016-12-28

How to Cite

1.
Mashhood AA, Rauf S, Qureishi SM. Male sexual disorders. J Pak Assoc Dermatol [Internet]. 2016Dec.28 [cited 2024Nov.2];15(4):323-38. Available from: https://www.jpad.com.pk/index.php/jpad/article/view/667

Issue

Section

Review Articles

Most read articles by the same author(s)

1 2 3 > >>